Last reviewed · How we verify
Prolonged sedation with midazolam
Prolonged sedation with midazolam is a marketed product developed by University Hospital, Rouen, with a key composition patent expiring in 2028. The drug's key strength lies in its established market presence and long-term use for sedation. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Prolonged sedation with midazolam |
|---|---|
| Sponsor | University Hospital, Rouen |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Extubation Delay After Prolonged Sedation (PHASE4)
- Effect of Bronchoscopy on the Outcome of Patients With Severe Sepsis With ARDS and Complicated by VAP From Prolonged Ventilation (PHASE1, PHASE2)
- Effect of Bronchoscopy on the Outcome of Patients With Severe Sepsis With ARDS and Complicated by VAP From Prolonged Ventilation (PHASE1, PHASE2)
- Inhalation of Sevoflurane Versus Intravenous Midazolam,Ketamine,Propofol For Pediatrics Undergoing Upper GI Endoscopy (NA)
- Effect of Bronchoscopy on the Outcome of Patients With Severe Sepsis With ARDS and Complicated by VAP From Prolonged Ventilation (PHASE1, PHASE2)
- Sevoflurane in Subarachnoidal Haemorrhage (PHASE2)
- Individualized Approach vs. Fixed Approach (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prolonged sedation with midazolam CI brief — competitive landscape report
- Prolonged sedation with midazolam updates RSS · CI watch RSS
- University Hospital, Rouen portfolio CI